BACKGROUND: In 2005, the French Government implemented a new way of financing high-cost drugs for hospitals in order to promote innovation. Such drugs are gathered on a positive list, established by the Ministry of Health, with a reimbursement price cap. Hospitals still negotiate with...

B. Dormont entend combattre l'idée selon laquelle les dépenses de santé vont croître du fait du vieillissement de la population. L'augmentation serait due, d'après elle, aux changements de pratiques dans la consommation des soins, laquelle tient en partie aux innovations médicales, ce qui...

The purpose of this paper is to study hospital costs in the event of introduction of a Prospective Payment System in France. We use a nested three dimensional database (stays-hospitals-years) to identify hospital unobservable heterogeneity and a transitory moral hazard component of cost...

The strategy currently adopted in France to deal with the ever-growing health expenditures is one of freezing compulsory deductions and broadening the scope of complementary insurance, while at the same time reaffirming that such insurance is optional. But individual freedom to take out...

En France, malgré le rôle prépondérant de l’assurance maladie obligatoire au financement des dépenses de santé (75,9% en moyenne en 2012), l’accès aux soins est fortement dépendant de la possession d’un contrat d’assurance complémentaire santé, et de sa qualité, dont 5% de la...

This paper uses a French reform to evaluate the impacts of price regulation on general practitioners (GP) care provision, fees, and income. This reform has restricted, since 1990, the conditions self-employed GPs have to fulfill to be allowed to over-bill. We exploit 2005 and 2008 Public Health...

This paper offers an integrated view of the relationships between health spending, medical innovation, health status, growth and welfare. Health spending triggers technological progress, which is a potential source of better outcomes in terms of longevity and quality of life, a direct source of...